News and Events

JP Morgan 2017 Healthcare Conference
NexImmune executives attend the JP Morgan Healthcare Conference on January 8-12, 2017 in San Francisco.

Society for Immunotherapy for Cancer 
NexImmune executives attend the annual meeting of the Society for Immunotherapy of Cancer on November 6-9, 2014 in National Harbor, Maryland.  

BIO 2014 International Convention
NexImmune executives attend Bio 2014 International Convention from June 23-26, 2014 in San Diego.  

JP Morgan 2014 Healthcare Conference
NexImmune executives attend the conference from January 13-16, 2014 in San Francisco. 
BioPharma America 2013
NexImmune executives attend BioPharma America from September 17-19, 2013 in Boston.
BIO 2013 International Convention
NexImmune executives attend the BIO 2013 International Convention on April 22 - 25, 2013 for business development meetings. 
University Research & Entrepreneurship Symposium
NexImmune executives present an overview of the company at the symposium on April 3, 2013 in Cambridge, MA.
JP Morgan 2013 Healthcare Conference
NexImmune executives attend the conference from January 7-9, 2013.
BIO 2012 International Convention 
NexImmune President & CEO Kenneth Carter attends the BIO 2012 International Convention on June 18-21 for business development meetings.
BIO-Europe 2012 Conference
NexImmune executives attend BIO-Europe 2012  on March 19-21 for business development meetings.
JP Morgan 2012 Healthcare Conference
NexImmune executives attend the conference on January 9-12 and present at BioTech Showcase 2012. 

NexImmune Acquired; Names New Board of Directors

Novel Approach to Adoptive Immunotherapy Developed by NexImmune’s Scientific Co-Founders
Technology provides rapid validation of patient-specific neoantigens as potential targets for individualized cancer therapy Publication Link

NexImmune’s AIM Immunotherapy Technology

Enables Novel Adoptive Immunotherapy Approach for the Treatment of Cancer  Publication Link

SBIR Grant
NexImmune recevies an SBIR grant of $290,000 from the NIH for the development of a human therapeutic based on AIM Technology.
State of Maryland Grant
NexImmune receives an extension of its translational R&D grant for $125,000 from the state. 
Kenneth Carter, PhD, as President and CEO and Jonathan Schneck, MD, PhD as Chairman of Clinical and Scientific Advisory Board; Licenses Technology From The Johns Hopkins University....

Johns Hopkins Technology
Transfer Office Licenses New Technology to NexImmune for the Development of Cancer Immune Therapies ....